BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

154 related articles for article (PubMed ID: 28440086)

  • 1. DEBIRI plus capecitabine: a treatment option for refractory liver-dominant metastases from colorectal cancer.
    Di Noia V; Basso M; Marsico V; Cerchiaro E; Rossi S; D'Argento E; Strippoli A; Schinzari G; Iezzi R; Cassano A; Barone C
    Future Oncol; 2019 Jul; 15(20):2349-2360. PubMed ID: 28440086
    [No Abstract]   [Full Text] [Related]  

  • 2. Trans-Arterial Chemoembolization with Irinotecan-Loaded Drug-Eluting Beads (DEBIRI) and Capecitabine in Refractory Liver Prevalent Colorectal Metastases: A Phase II Single-Center Study.
    Iezzi R; Marsico VA; Guerra A; Cerchiaro E; Cassano A; Basso M; Devicienti E; Rodolfino E; Barone C; Bonomo L
    Cardiovasc Intervent Radiol; 2015 Dec; 38(6):1523-31. PubMed ID: 25799948
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Randomized controlled trial of irinotecan drug-eluting beads with simultaneous FOLFOX and bevacizumab for patients with unresectable colorectal liver-limited metastasis.
    Martin RC; Scoggins CR; Schreeder M; Rilling WS; Laing CJ; Tatum CM; Kelly LR; Garcia-Monaco RD; Sharma VR; Crocenzi TS; Strasberg SM
    Cancer; 2015 Oct; 121(20):3649-58. PubMed ID: 26149602
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Efficacy and Toxicity of Hepatic Intra-Arterial Drug-Eluting (Irinotecan) Bead (DEBIRI) Therapy in Irinotecan-Refractory Unresectable Colorectal Liver Metastases.
    Bhutiani N; Akinwande O; Martin RC
    World J Surg; 2016 May; 40(5):1178-90. PubMed ID: 26711640
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Early Experience with 70-150 μm Irinotecan Drug-eluting Beads (M1-DEBIRI) for the Treatment of Unresectable Hepatic Colorectal Metastases.
    Akinwande O; Scoggins C; Martin RC
    Anticancer Res; 2016 Jul; 36(7):3413-8. PubMed ID: 27354601
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Transarterial chemoembolization using DEBIRI for treatment of hepatic metastases from colorectal cancer.
    Narayanan G; Barbery K; Suthar R; Guerrero G; Arora G
    Anticancer Res; 2013 May; 33(5):2077-83. PubMed ID: 23645758
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Concomitant capecitabine with hepatic delivery of drug eluting beads in metastatic colorectal cancer.
    Akinwande O; Miller A; Hayes D; O'Hara R; Tomalty D; Martin RC
    Anticancer Res; 2014 Dec; 34(12):7239-45. PubMed ID: 25503155
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Hepatic intra-arterial injection of drug-eluting bead, irinotecan (DEBIRI) in unresectable colorectal liver metastases refractory to systemic chemotherapy: results of multi-institutional study.
    Martin RC; Joshi J; Robbins K; Tomalty D; Bosnjakovik P; Derner M; Padr R; Rocek M; Scupchenko A; Tatum C
    Ann Surg Oncol; 2011 Jan; 18(1):192-8. PubMed ID: 20740319
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Intra-arterial hepatic beads loaded with irinotecan (DEBIRI) with mFOLFOX6 in unresectable liver metastases from colorectal cancer: a Phase 2 study.
    Pernot S; Pellerin O; Artru P; Montérymard C; Smith D; Raoul JL; De La Fouchardière C; Dahan L; Guimbaud R; Sefrioui D; Jouve JL; Lepage C; Tougeron D; Taieb J;
    Br J Cancer; 2020 Aug; 123(4):518-524. PubMed ID: 32507854
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Capecitabine plus oxaliplatin and irinotecan regimen every other week: a phase I/II study in first-line treatment of metastatic colorectal cancer.
    Bajetta E; Celio L; Ferrario E; Di Bartolomeo M; Denaro A; Dotti K; Mancin M; Bajetta R; Colombo A; Pusceddu S
    Ann Oncol; 2007 Nov; 18(11):1810-6. PubMed ID: 17823385
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Prognostic Value of TACE With Irinotecan-loaded Drug-eluting Beads (DEBIRI) in Patients With Liver Metastases from Unresectable Colorectal Cancer.
    Ishikawa T; Imai M; Sato R; Jimbo R; Kobayashi Y; Sato T; Iwanaga A; Sano T; Yokoyama J; Honma T
    Anticancer Res; 2023 Aug; 43(8):3647-3651. PubMed ID: 37500124
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Does Bead Size Affect Patient Outcome in Irinotecan-Loaded Beads Chemoembolization Plus Systemic Chemotherapy Regimens for Liver-Dominant Colorectal Cancer? Results of an Observational Study.
    Boeken T; Moussa N; Pernot S; Abed A; Dean C; Taieb J; Sapoval M; Pellerin O
    Cardiovasc Intervent Radiol; 2020 Jun; 43(6):866-874. PubMed ID: 32103303
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Transarterial Chemoembolisation of Colorectal Liver Metastases with Irinotecan-Loaded Beads: A Bi-institutional Analysis of 125 Treatments in 53 Patients.
    Ngo A; von Stempel C; Corbo B; Bandula S; Shiu KK; Raja J; Hague J; Evans J; Kibrya N
    Cardiovasc Intervent Radiol; 2019 Jul; 42(7):979-990. PubMed ID: 31044294
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Intra-arterial infusion of irinotecan-loaded drug-eluting beads (DEBIRI) versus intravenous therapy (FOLFIRI) for hepatic metastases from colorectal cancer: final results of a phase III study.
    Fiorentini G; Aliberti C; Tilli M; Mulazzani L; Graziano F; Giordani P; Mambrini A; Montagnani F; Alessandroni P; Catalano V; Coschiera P
    Anticancer Res; 2012 Apr; 32(4):1387-95. PubMed ID: 22493375
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Neoadjuvant therapy of bevacizumab in combination with oxaliplatin and capecitabine (XELOX) for patients with metastatic colorectal cancer with unresectable liver metastases: a phase II, open-label, single-arm, noncomparative trial.
    Chen HH; Lin JK; Chen JB; Chuang CH; Liu MC; Wang JY; Changchien CR
    Asia Pac J Clin Oncol; 2018 Feb; 14(1):61-68. PubMed ID: 28906589
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Bi-weekly Capecitabine-Oxaliplatin (XELOX) plus Bevacizumab as First-line Treatment of Metastatic Colorectal Cancer -The PHOENiX Trial.
    Matsui T; Nagata N; Hirata K; Okazaki S; Sato S; Nakamura M; Kim H; Oba K; Sakamoto J; Mishima H
    Anticancer Res; 2016 Jul; 36(7):3437-43. PubMed ID: 27354605
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Radiological assessment of response to neoadjuvant transcatheter hepatic therapy with irinotecan-eluting beads (DEBIRI(®)) for colorectal liver metastases does not predict tumour destruction or long-term outcome.
    Jones RP; Stättner S; Dunne DF; O'Grady E; Smethurst A; Terlizzo M; Malik HZ; Fenwick SW; Poston GJ
    Eur J Surg Oncol; 2013 Oct; 39(10):1122-8. PubMed ID: 23928482
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Transarterial chemoembolization with irinotecan beads in the treatment of colorectal liver metastases: systematic review.
    Richardson AJ; Laurence JM; Lam VW
    J Vasc Interv Radiol; 2013 Aug; 24(8):1209-17. PubMed ID: 23885916
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Bradycardia associated with drug-eluting beads loaded with irinotecan (DEBIRI) infusion for colorectal liver metastases.
    Pua U
    Cardiovasc Intervent Radiol; 2013 Jun; 36(3):864-6. PubMed ID: 22722719
    [TBL] [Abstract][Full Text] [Related]  

  • 20. PARAGON II - A single arm multicentre phase II study of neoadjuvant therapy using irinotecan bead in patients with resectable liver metastases from colorectal cancer.
    Jones RP; Malik HZ; Fenwick SW; Terlizzo M; O'Grady E; Stremitzer S; Gruenberger T; Rees M; Plant G; Figueras J; Albiol M; Adam R; Awad S; Poston GJ
    Eur J Surg Oncol; 2016 Dec; 42(12):1866-1872. PubMed ID: 27561844
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.